Jim Cramer on Palantir Technologies Inc. (PLTR): ‘It Just Gets Better And Better’
We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...
Jim Cramer on Palantir Technologies Inc. (PLTR): ‘It Just Gets Better And Better And Butt Better’
We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...
Palantir To Face DOGE: Potential Bogeyman Through The Next 4 Years
DOGE's push for transparency and cost efficiency threatens Palantir's government contracts. Read more to see why PLTR stock ...
Think Palantir Stock Is Expensive? This Chart Might Change Your Mind.
Palantir Technologies (NASDAQ: PLTR) has been one of the hottest stocks in the artificial intelligence (AI) space. Palantir ...
24/7 Wall St14h
Palantir Technologies (PLTR) Price Prediction and Forecast 2025-2030
Demand for Big Data services is increasing. Palantir, a leader in the field, should benefit. Here are the forecasts and price ...
Analysts Think This Under-the-Radar AI Stock Could Rally 20% From Here
Detailed price information for Palantir Technologies Inc Cl A (PLTR-Q) from The Globe and Mail including charting and trades.
Snowflake: There's A Lot To Like In 2025
Snowflake's $342B TAM by 2028 and aggressive investments in AI and new products position it to capture substantial market ...
Hosted on MSN23h
Palantir Stock On Track To Snap 5-Session Losing Streak Despite Sell-Side Prediction For More Weakness: Retail Hopes Worst May Be Behind
Palantir Technologies, Inc. ($PLTR) stock could snap its five-session losing streak as it climbed in Tuesday’s premarket. The ...
Where Will Palantir Technologies Be in 3 Years?
Palantir Technologies ( PLTR 1.43%) went public in September 2020, and shares of the company that made its name by providing ...
Could Artificial Intelligence (AI) Agents Dethrone Palantir in 2025?
Palantir emerged as one of the best pure-play AI investments in 2024. The stock had a phenomenal year, rising 340%. However, ...
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...
Large-cap U.S. stocks may be heading for a lost decade, this contrarian warns. What to buy instead.
"In 1837, 1873, 1929, 1973, 1999, and again in 2024, U.S. stocks reached extremely high valuations relative to their profit growth. Each time this was followed by a loss of more than 80% on average ...